Table 1.
NPs as drug carriers without targeting ligands in liver fibrosis treatment.
| Nanoparticle Systems | NPs Formulation | Delivered Drug | Reference |
|---|---|---|---|
| Lipid-based NPs | RNA oligonucleotide-liposomal | MTL-CEBPA | [70] |
| Cationic lipid NPs | small interfering RNA to the procollagen 1(I) gene | [20] | |
| Dexamethasone-liposomes | dexamethasone | [71] | |
| Polymer-based NPs | Cationic nanohydrogel particles | anti-Col1α1 siRNA | [72] |
| Ketal cross-linked cationic nanohydrogel | Cy5-labeled anti-col1α1 siRNA | [73] | |
| PLGA | phyllanthin | [74] | |
| PEG-PLGA or PEG-PLGA/PLGA NPs | sorafenib | [75] | |
| Eudragit(R) RS100 NPs (SMnps) | silymarin | [76] | |
| Inorganic NPs | Rhodamine B (RhB)-mesoporous silica NPs (MSNs-RhB | salvianolic acid B | [77] |
| Mesoporous silica NPs | siTnC | [78] | |
| PEG-AuNPs | hesperetin | [79] | |
| AuNPs and SiNPs | NO donors | [80] | |
| PtNPs | Curcumin | [81] | |
| Calcium phosphate NPs (CaP@BSA NPs) | TSG-6 | [82] | |
| Graphene nanostars linked to PAMAM-GS dendrimer | Plasmid | [83] | |
| Protein NPs | Zein nanospheres | Curcumin | [84] |
| Glucose modify albumin NPs | Berberine | [85] | |
| Albumin NPs | Bexamethasone | [22] | |
| Polyavidin-based NPs | Dexamethasone | [86] |